

In re: Cagle et al.

Serial Number: 10/706,759

Confirmation No: 7815

Filed: November 12, 2003

For: "The Use of an Anti-Allergy Agent and a

Steroid To Treat Nasal Conditions"

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97(b)(3)

Commissioner for Patents P. O. Box 1450 Alexandria VA 22313-1450

Sir:

Applicants submit the attached PTO Form 1449 and copy of one (1) reference prior to the mailing date of a first Office Action on the merits in the above-referenced application.

Applicants request that the references listed in the accompanying PTO Form 1449 be considered during prosecution of the above-referenced application, and that these references appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

ALCON

Date: 4/21/04

By:

Patrick M. Ryan Reg. No. 36,263

ADDRESS FOR CORRESPONDENCE: R&D Counsel Q-148 Alcon Research, Ltd. 6201 South Freeway Fort Worth, Texas 76134-2099 (817) 551-3066 Atty. Docket No. 2442 I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this date:

Jeannie Burke

Sheet 1 of 1 Form PTO-1449 U.S. Dept. of Commerce ATTY: DOCKET NO. P SERIAL NO. CONFIRMATION NO. Patent & Trademark Office 2442 10/706,759 7815 LIST OF DOCUMENTS CITED BY APPLICANT **APPLICANT** Cagle et al. (Use several sheets if necessary) FILING DATE GROUP November 12, 2003 1614 U.S. PATENT DOCUMENTS **EXAMINER** DOCUMENT DATE NAME CLASS SUBCLASS **FILING DATE** INITIAL NUMBER IF **APPROPRIATE** AA AB AC AD AE AF AG AH ΑÏ AJ AK FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS **SUBCLASS TRANSLATION** NUMBER YES NO AL AM AN AO AP OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) AR Lanier et al., "Comparision of the Efficacy of Combined Fluticasone Propionate and Olopatadine Vesus Combined

EXAMINER	DATE CONSIDERED
	DATE CONSIDERED
	<u> </u>

Fluticasone Propionate and Fexofenadine for the Treatment of Allergic Rhinoconjunctivitis Induced by Conjunctival

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Allergen Challenge," Clinical Therapeutics, Vol. 24(7), pp. 1161-1174 (2002)

AS AT